People aged 1+ years living with type 1 diabetes (T1D) in Australia have funded access to Tresiba® Penfill from 1 July 2026. Also known as insulin degudec, Tresiba® Penfill is an ultra long-acting basal insulin, taken once daily at flexible times.
Novo Nordisk, which makes Tresiba® Penfill, has today announced that the insulin is listed on the Pharmaceutical Benefits Scheme (PBS). This means it is now subsidised by the Australian Government.
Breakthrough T1D welcomes any increase in the range of insulins available on the PBS, allowing people with T1D in Australia to access them at a reduced cost.
Sydney Yovic, CEO of Breakthrough T1D, said:Â
As a leading funder of type 1 diabetes research, Breakthrough T1D is excited about the progress and innovation happening in this space, which is crucial for making the relentless management of type 1 diabetes easier and safer.
Everyone living with T1D relies on insulin to manage their condition, but people have varied needs and preferences for types of insulin. Different forms of insulin work at different speeds, ranging from rapid-acting to ultra long-acting, like Tresiba® Penfill.
Most people with T1D follow a basal- bolus regime, which involves taking a long-acting insulin once or twice a day (known as a basal dose) and a short-acting insulin when glucose levels rise throughout the day (known as bolusing).
Novo Nordisk is currently testing a new once-weekly basal insulin called insulin icodec in an international clinical trial that includes Australia.
